TTN antisense RNA 1 (TTN-AS1)

TTN antisense RNA 1 (TTN-AS1) is a long noncoding RNA transcribed antisense to the human TTN gene. It is primarily localized in the nucleus and regulates TTN gene expression through both transcriptional and post-transcriptional mechanisms, including promoting TTN promoter activity, stabilizing TTN mRNA, and influencing alternative splicing[1][4]. TTN-AS1 additionally functions as a competing endogenous RNA, binding and sequestering multiple microRNAs (such as miR-133b, miR-211-5p, miR-376a), which in turn derepresses the expression of oncogenic targets and contributes to carcinogenesis in a broad range of cancers[2][3][5]. Knockdown of TTN-AS1 leads to reduced cancer cell proliferation, migration, and invasion, and increases apoptosis[2][3][5]. TTN-AS1 expression levels correlate with negative clinical outcomes and may serve as a biomarker for diagnosis and prognosis in cancer[1][3][5]. TTN-AS1 is also implicated in regulation of alternative splicing in cardiac muscle by interacting with RBM20 and TTN mRNA[4]. No approved drugs currently target TTN-AS1 directly, but its role in cancer and heart disease makes it a promising candidate for future RNA-based therapeutics[1][3][5].

Other names

TTN antisense RNA 1 (non-protein coding)TTN-AS1LOC101927055titin-antisense RNA 1

Mechanisms of drugs would include inhibition of TTN-AS1 transcription, blocking TTN-AS1–miRNA interactions, or use of antisense oligonucleotides to degrade TTN-AS1 transcripts